For Institutional Investors in the US

Andy Acker, CFA

Global Life Sciences | Portfolio Manager
Andy Acker, CFA | Janus Henderson Investors

Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners.

Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 26 years of financial industry experience.

Download hi-res headshot

Products Managed

Articles Written

Signs of recovery in biotech?
Timely & Topical

Signs of recovery in biotech?

Low valuations, positive clinical trial data and clarity around drug pricing reform could help revive the sector’s beaten-down stocks.

Exploring the science – and business – of biotech
Features & Outlooks

Exploring the science – and business – of biotech

A discussion on potential investment opportunities in health care despite a record sell-off in small- and mid-cap biotech stocks.

Health care strikes a balance
Features & Outlooks

Health care strikes a balance

Why health care could be well positioned to offer both defense against market volatility and opportunities for long-term growth.

Making sense of drug pricing reform for investors
Timely & Topical

Making sense of drug pricing reform for investors

Why we believe the biopharma industry should be able to adapt to drug pricing changes.

Health Care’s Recession Playbook
Analysis & Studies

Health Care’s Recession Playbook

Some areas of health care benefit from steady demand and the ability to pass on price increases – appealing qualities amid slowing economic growth.

How Weight Loss Could Yield Gains for Investors

How Weight Loss Could Yield Gains for Investors

A breakthrough in anti-obesity medication could help millions of people struggling with excess weight and create a new growth opportunity for health care investors.

Century of Biotech: Capitalizing on the Biomedical Revolution

Century of Biotech: Capitalizing on the Biomedical Revolution

Remarkable advances in biomedical research are leading to rapid growth and volatility in the biotechnology sector.

Amid Volatility, Health Care’s Appeal Grows

Amid Volatility, Health Care’s Appeal Grows

The sector could offer defense, as well as opportunities for long-term gains, in today’s uncertain financial markets.

Can Biotech Bounce Back?
Features & Outlooks

Can Biotech Bounce Back?

For more than a year, biotechnology stocks have been deep in the red, even as medical breakthroughs continue – a disconnect we think is unlikely to last.

From Defense to Offense in Biotech

From Defense to Offense in Biotech

Why the beaten-down sector may be worth another look.

Opportunities in Health Care in 2022

Opportunities in Health Care in 2022

COVID-19 has had an outsize influence on health care stocks. With the pandemic hopefully retreating, what’s next for the sector?

Unlocking Value in Health Care Stocks
Analysis & Studies

Unlocking Value in Health Care Stocks

Fewer COVID-related disruptions and less regulatory uncertainty could give overlooked areas of health care a boost in 2022.